Recursion Pharmaceuticals
RXRX
270 hedge funds and large institutions have $1.89B invested in Recursion Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 110 increasing their positions, 48 reducing their positions, and 46 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 110 | Existing positions reduced: 48
52% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 46
8% more funds holding
Funds holding: 249 → 270 (+21)
7.21% more ownership
Funds ownership: 102.25% → 109.46% (+7.2%)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
11% less capital invested
Capital invested by funds: $2.12B → $1.89B (-$234M)
45% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $22.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$134M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$48.3M |
| 3 |
BlackRock
New York
|
+$43.5M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$31M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$14M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$12.3M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$10.7M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.32M |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$6.59M |
RXRX Hedge Fund Activity: Q2 2024 in Review
270 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q2 2024, worth a combined $1.89B — down 11% from $2.12B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new RXRX positions and 46 closed out — a net gain of 24 holders — while 110 added to existing stakes and 48 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $134M. The largest seller was State Street, cutting an estimated $14M.
- 270 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q2 2024, up from 249 in Q1 2024.
- Funds reported $1.89B of Recursion Pharmaceuticals stock for Q2 2024, down 11% quarter-over-quarter.
- 70 funds opened new Recursion Pharmaceuticals positions in Q2 2024 and 46 closed out, a net change of +24 holders.
- The largest Recursion Pharmaceuticals buyer in Q2 2024 was RA Capital Management, an estimated $134M added.
- The largest Recursion Pharmaceuticals seller in Q2 2024 was State Street, an estimated $14M sold.
Based on aggregated 13F filings for Q2 2024.